<DOC>
	<DOCNO>NCT00709891</DOCNO>
	<brief_summary>This study provide data performance Cobas® 4800 HPV Test identify histologically confirm high-grade cervical disease . The baseline , cross-sectional phase conduct approximately 45,000 woman undergo routine cervical cancer screening , approximately 7,400 select undergo colposcopy biopsy/endocervical curettage ( ECC ) baseline . These subject include woman cytology 'not normal ' selection 'normal ' cytology enter follow-up phase underwent cytological evaluation annually 3 year . In follow-up phase , colposcopy biopsy/ECC perform woman cervical cytology consider 'not normal ' annual follow-up visit .</brief_summary>
	<brief_title>Evaluation Cobas® 4800 HPV Test Detection High-grade Cervical Disease</brief_title>
	<detailed_description />
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Uterine Cervical Diseases</mesh_term>
	<criteria>Females ≥ 21 year age present routine cervical cancer screening . An intact cervix . Willing able undergo colposcopy biopsy endocervical curettage within 8 week study Visit 1 . Known pregnancy study Visit 1 . Presenting colposcopy study Visit 1 . Any condition result increase risk bleed biopsy . Hysterectomy . Known history ablative excisional therapy cervix within precede 12 month .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>